Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atypical antipsychotics
Pharma
Otsuka, Lundbeck's Rexulti snubbed by FDA in PTSD
Otsuka and Lundbeck said the FDA will require new clinical trials if the partners wish to pursue a Rexulti PTSD approval in the future.
Fraiser Kansteiner
Sep 22, 2025 4:42pm
BMS touts commercial execution, reckons with clinical setbacks
Jul 31, 2025 11:10am
FDA advisors overwhelmingly reject Lundbeck, Otsuka's PTSD drug
Jul 21, 2025 11:34am
FDA questions Rexulti efficacy in PTSD after failed phase 3
Jul 16, 2025 2:38pm
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
